Review: Nonselective nonsteroidal antiinflammatory drugs do not increase risk for cardiovascular events
- Understanding NSAIDs, CV risks. Tanzi, Maria G. // Pharmacy Today;Sep2011, Vol. 17 Issue 9, p67
The article presents studies on the association between cardiovascular risks and the use of nonsteroidal anti-inflammatory agents (NSAIDs). The report, from a meta-analysis, proposes that cardiovascular risk is related with selective and nonselective NSAIDs. Other data revealed an increased risk...
- NSAIDs may worsen enlarged prostate symptoms. // Urology Times;Nov2007, Vol. 35 Issue 14, p20
The article reports on the study which found that painkillers, such as ibuprofen and naproxen, may lower the risk of developing an enlarged prostate and worsen urinary symptoms in men who already have the condition, as in the article published in "Harvard Men's Health Watch." According to the...
- Naproxen the most heart-friendly NSAID? // Clinical Advisor;Nov2011, Vol. 14 Issue 11, p24
The article reports that naproxen and ibuprofen had the lowest risk to raise cardiovascular event as suggested by nonsteroidal anti-inflammatory drugs (NSAIDs).
- Chemopreventive Effect of NSAID Use on the Risk of Breast Cancer: The Jury is Still Out. Yuqing Zhang; Jingbo Niu // Current Medical Literature: Breast Cancer;2006, Vol. 18 Issue 1, p1
Discusses the effects of non-steroidal anti-inflammatory drugs (NSAID) on the occurrence of breast cancer. Use of NSAID in the treatment of certain conditions including arthritis, headache, muscular pain, inflammation and fever; Frequently prescribed NSAID including ibuprofen and naproxen;...
- A primer on pain relief. // Consumer Reports;Nov2010, Vol. 75 Issue 11, p10
The article presents information on the differences between the nonsteroidal anti-inflammatory agents aspirin, ibuprofen and naproxen. The advantages and drawbacks of these analgesics are noted. Aspirin, also known as acetylsalicylic acid, can help to prevent blood clots, but is linked to Reye's...
- Lumiracoxib reduced ulcer complications compared with ibuprofen and naproxen in osteoarthritis and did not increase cardiovascular outcomes. // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p46
The article cites a study which presents a comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial. The study was published in the 2004 issue of the journal "Lancet." In all patients and in those not taking low-dose aspirin,...
- COMMENTARY: Lumiracoxib reduced ulcer complications compared with ibuprofen and naproxen in osteoarthritis and did not increase cardiovascular outcomes. Hart, Lawrence // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p47
The article comments on a study which presents a comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET). The major conclusions reported by TARGET were that lumiracoxib showed a 3 to 4 fold reduction in ulcer...
- Pain Pills Cause Hidden Damage. Harrar, Sarí; Verkler, Erin // Prevention;Nov2003, Vol. 55 Issue 11, p175
Discusses research on the gastrointestinal (GI) damage caused by painkillers with naproxen or ibuprofen, called nonsteroidal anti-inflammatory drugs (NSAIDs). Ways to limit the damage; Effect of NSAIDs on the GI tract.
- News in brief . . . // Reactions Weekly;6/4/2005, Issue 1054, p4
Presents three medical research. Results of a study on the comparison of esomeprazole, lansoprazole and pantoprazole; Information on a study on nonsteroidal anti-inflammatory drug; Facts about a study on the cardiovascular risk factors after antenatal exposure to betamethasone.